News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Analysts on Wall Street project that Monolithic Power (MPWR) will announce quarterly earnings of $5.88 per share in its forthcoming report, representing an increase of 39.7% year over year. Revenues are projected to reach $903.97 million, increasing 36% from the same quarter last year. …
Sharemaestro market context Trend signal active 52 weeks +55.1% · Next-week setup negative 26.5%Monopar Therapeutics Inc (MNPR) has an institutional shareholding score of 7.00, placing it 80th out of 386 in the Biotechnology & Medical Research industry. The institutional shareholding proportion is 88.03%, marking a 29.07% increase quarter-over-quarter. Janus Henderson Investors, RA Capital Management, LP, and Adage …
The article provides a detailed historical overview of Monopar Therapeutics Inc (MNPR) dividends and stock splits. It indicates that no dividends have been distributed by the company over the past five years and lists multiple upcoming stock splits of type "Merger" with a 5-to-1 …
Monolithic Power Systems (MPWR) is set to report its Q2 2026 earnings, with strong growth expected due to increasing demand for power management ICs in AI servers, GPUs, and accelerator platforms. The company has a positive Earnings ESP and a Zacks Rank #2, indicating …
Investors in Monolithic Power Systems, Inc. MPWR need to pay close attention to the stock based on moves in the options market lately. That is because the Sept. 18, 2026 $560.00 Call had some of the highest implied volatility of all equity options today. …
Sharemaestro market context Trend signal active 52 weeks +55.1% · Next-week setup negative 26.5%Clough Capital Partners L P has acquired a new stake of 1,457 shares in Monolithic Power Systems, Inc. (NASDAQ:MPWR) valued at approximately $1,593,000. Other institutional investors have also adjusted their holdings in the semiconductor company. Despite some recent insider selling by executives, analysts have …
This article details the shareholder structure of Monopar Therapeutics Inc (MNPR), listing its major shareholders and institutional holdings. Key institutional investors include Janus Henderson Investors, RA Capital Management, L.P., and Adage Capital Management, L.P., alongside an overview of institutional shareholding trends over recent quarters. …
This article from TradingKey reports on Monopar Therapeutics Inc (MNPR)'s revenue breakdown. It states that relevant data regarding business segments, regional revenue, and profit contribution have not yet been disclosed by the company. The article also provides the current stock trading information for MNPR.
The Public Employees Retirement System of Ohio has reduced its stake in Monolithic Power Systems, Inc. by 4.4% in the first quarter, selling 976 shares. Despite this, other institutional investors significantly increased their holdings in the semiconductor company. Analysts maintain a "Moderate Buy" rating …
This article provides the quarterly and annual cash flow statements and related financial data for Monopar Therapeutics Inc (MNPR). It details operating, investing, and financing cash flows, along with changes in net income, working capital, and cash balances over various fiscal quarters from 2017 …
Andra AP fonden significantly cut its stake in Monolithic Power Systems (MPWR) by selling 93.7% of its holdings in Q1. Despite the reduction by this institutional investor, Monolithic Power Systems reported strong Q1 results, beating analyst expectations for both EPS and revenue, with revenue …
Shares of several semiconductor companies, including Lattice Semiconductor, Allegro MicroSystems, Monolithic Power Systems, Marvell Technology, and MACOM, fell after the U.S. government announced new tariffs on 60 trading partners over forced labor concerns. These tariffs, impacting key semiconductor supply chain nations, are expected to …
The market expects Monolithic Power (MPWR) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2026. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might …
Sharemaestro market context Trend signal active 52 weeks +55.1% · Next-week setup negative 26.5%H.C. Wainwright has raised its target price for MONOPAR THERAPEUTICS INC. to $125 from the previous $105. This news was reported by Reuters. The article is very short, focusing solely on this price update.
Monolithic Power Systems (MPWR) stock is trading near record highs, reflecting strong demand for its power management chips, particularly from data center, automotive, and industrial clients, and aided by AI-related growth. The company reported double-digit revenue and net income growth in fiscal 2024, with …
H.C. Wainwright has increased its price target for Monopar Therapeutics (NASDAQ:MNPR) to $125 from $105, maintaining a Buy rating, following Monopar's initiation of a rolling NDA submission for ALXN1840 for Wilson disease. The stock has seen a significant 140% increase over the past year. …
Monopar Therapeutics has released a proxy filing summary detailing an Annual Meeting scheduled for August 5, 2024. Stockholders will vote on four proposals: election of six directors, ratification of BPM LLP as auditor, approval of a reverse stock split, and an amendment to the …
Monopar Therapeutics has initiated a rolling application for ALXN1840, a drug designed to treat Wilson disease, in collaboration with Alexion. This marks a significant step towards regulatory approval for patients suffering from this rare genetic disorder. The application process will allow for continuous submission …
Monopar Therapeutics Inc. has begun a rolling New Drug Application (NDA) submission to the U.S. FDA for ALXN1840 (tiomolibdate choline, TMC) to treat Wilson disease. This first-in-class therapy, which has received Fast Track, Orphan Drug, and Rare Pediatric Disease designations, would be the first …
Independent Financial Group LLC has acquired a new position in Monolithic Power Systems, Inc. (NASDAQ:MPWR) during the first quarter, purchasing 762 shares valued at approximately $833,000. Institutional investors now control 93.46% of the semiconductor company's stock, with several firms increasing their holdings. Analysts maintain …
Monolithic Power Systems (MPWR) stock has dropped 22% from its 52-week high, despite strong Q1 revenue and Q2 guidance. Wells Fargo recently trimmed its price target but maintained an Overweight rating, still implying significant upside for the stock. The article highlights the tension between …
Monopar Therapeutics (MNPR) is a clinical-stage biotech focused on cancer treatments, with its stock valuation tied to pipeline progress and financing. The company reported increased operating expenses and a net loss in 2025 due to expanded research, funded by equity offerings. Investors are closely …
Monopar Therapeutics Inc. has enhanced its commercial leadership team by appointing Nicole Sweeny to its Board of Directors and hiring Sharon Funk and Daniel Olmstead for key commercial roles. These strategic additions aim to support the anticipated launch of ALXN1840, Monopar's first commercial product …
Monopar (Nasdaq: MNPR) announced key commercial leadership additions to support the anticipated launch of its first potential commercial product, ALXN1840, for Wilson disease. Nicole Sweeny, former Chief Commercial Officer of KalVista Pharmaceuticals, was elected to the Board of Directors, while Sharon Funk and Daniel …
Monopar Therapeutics (MNPR) is a clinical-stage oncology company that reported no revenue and a net loss of $10.9 million in 2023, relying on external funding for its pipeline. The company is advancing Validive for oral mucositis and camsirubicin for soft tissue sarcoma, with its …
Monolithic Power Systems (MPWR) stock is trading near record levels, reflecting sustained double-digit revenue and earnings growth. The company reported approximately $2.0 billion in revenue for fiscal 2025, an 18% increase year-over-year, with net income growing by nearly 19%. This strong financial performance, combined …
Maurice Sciammas, EVP of Worldwide Sales & Marketing at Monolithic Power Systems (NASDAQ: MPWR), sold approximately $20.2 million worth of company stock on July 15, 2026, as part of a Rule 10b5-1 trading plan. Despite MPWR's 85% return over the past year, InvestingPro analysis …
Maurice Sciammas, EVP of Worldwide Sales & Marketing at Monolithic Power (MPS), sold 14,986 common shares on July 15, with sales prices ranging from USD 1,314.03 to USD 1,405.71 per share. Following these transactions, his directly held stake in the company decreased to 151,644 …
Monolithic Power Systems, Inc. (MPS) announced it will release its second quarter 2026 financial results on Thursday, July 30, 2026, after the market closes. Following the release, the company will host a question-and-answer webinar at 2:00 p.m. PT / 5:00 p.m. ET to discuss …
Monolithic Power Systems (MPWR) shareholder Maurice Sciammas has filed a Form 144 notice to sell 15,000 common shares through Morgan Stanley Smith Barney LLC Executive Financial Services. The proposed sale is valued at $20,245,944.00, with an approximate sale date of July 15, 2026, on …
Maurice Sciammas, EVP of WW Sales & Marketing at Monolithic Power Systems (MPWR), sold 15,000 shares of common stock on July 15, 2026. These sales, totaling approximately $20.25 million, were executed across 18 transactions under a pre-arranged Rule 10b5-1 trading plan adopted in November …
Cantor Fitzgerald has reiterated an Overweight rating and a $109 price target for Monopar Therapeutics (NASDAQ:MNPR), ahead of an expected New Drug Application submission for ALXN1840 for Wilson disease. The firm highlighted Monopar's significant stock return and upward earnings revisions, while also addressing investor …
Search by ticker symbol or company name and select a result to open its chart.